Table 5 Antinuclear antibody detection during adalimumab treatment
Treatment | Week | Number of positive ANA sera (%) | ||
|---|---|---|---|---|
| Â | Â | ANA | Anti-dsDNA | Anti-ENA |
Adalimumab (n = 57) | 0 | 4 (7) | 0 (0) | 3 (5.2) |
| Â | 24 | 9 (16) | 2 (3.5) | 0 |
| Â | 48 | 12 (21) | 4 (7) | 2 (3.5) |
   Total |  | 16 (28) | 4 (7) | 5 (9) |
   P |  | <0.01 | <0.05 | n.s. |
Control RA (n = 55) | 0 | 5 (9) | 0 | 4 (7) |
| Â | 24 | 2 (3.5) | 0 | 0 |
| Â | 48 | 3 (5.2) | 0 | 1 (1.7) |
   Total |  | 8 (14.5) | 0 (0) | 5 (8.7) |
   P |  | n.s. |  | n.s. |